International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, Classification, and Pharmacology of G Protein-Coupled Melatonin Receptors

Pharmacological Reviews - Tập 62 Số 3 - Trang 343-380 - 2010
Margarita L. Dubocovich1,2,3,4,5,6,7, Philippe Delagrange1,2,3,4,5,6,7, Diana N. Krause1,2,3,4,5,6,7, David C. Klein1,2,3,4,5,6,7, Daniel P. Cardinali1,2,3,4,5,6,7, James Olcese1,2,3,4,5,6,7
1Department Molecular Pharmacology and Biological Chemistry, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (M.L.D.)
2Department of Biomedical Sciences, Florida State University College of Medicine, Tallahassee, Florida (J.O.)
3Department of Pharmacology and Toxicology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, New York (M.L.D.)
4Department of Pharmacology, College of Medicine, University of California, Irvine, California (D.N.K.)
5Department of Teaching & Research, Faculty of Medical Sciences, Pontificia Universidad Católica Argentina, Buenos Aires, Argentina (D.P.C.)
6Division of Reproduction and Endocrinology, School of Biomedical and Health Sciences, King's College London, United Kingdom (D.S.)
7Experimental Sciences Department, Institut de Recherches Servier, Suresnes, France (P.D.)

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1097/00001756-199812210-00011

10.1152/ajpendo.00478.2004

10.1056/NEJM200010123431510

10.1016/j.smrv.2004.05.002

Arnis, 1994, A conserved carboxylic acid group mediates light-dependent proton uptake and signaling by rhodopsin, J Biol Chem, 269, 23879, 10.1016/S0021-9258(19)51020-1

10.1016/j.bcp.2008.02.022

10.1007/s00210-003-0751-2

10.1046/j.1600-079X.2003.00095.x

10.1074/jbc.M200729200

10.1124/mol.104.000398

Balík, 2004, Melatonin action in neonatal gonadotrophs, Physiol Res, 53, S153, 10.33549/physiolres.930000.53.S153

Baldwin, 1993, The probable arrangement of the helices in G protein-coupled receptors, EMBO J, 12, 1693, 10.1002/j.1460-2075.1993.tb05814.x

10.1016/S0006-3495(00)76514-3

10.1124/mol.60.1.1

Ballesteros JA Weinstein H (1995) Integrated Methods for the Construction of Three-Dimensional Models and Computational Probing of Structure-Function Relations in G Protein-Coupled Receptors, in Methods in Neuroscience: Receptor Molecular Biology ( Sealfon SC ed) pp 366–428, Academic Press, San Diego.

Barrenetxe, 2004, Physiological and metabolic functions of melatonin, J Physiol Biochem, 60, 61, 10.1007/BF03168221

Barrett, 1997, Cloning and functional analysis of a polymorphic variant of the ovine Mel 1a melatonin receptor, Biochim Biophys Acta, 1356, 299, 10.1016/S0167-4889(96)00179-6

10.1034/j.1600-079X.2003.00090.x

10.1677/joe.1.06929

10.1111/j.1600-079X.1993.tb00903.x

10.1021/bi00220a027

Beresford, 1998, GR196429: a nonindolic agonist at high-affinity melatonin receptors, J Pharmacol Exp Ther, 285, 1239

10.1126/science.1067262

10.1158/0008-5472.CAN-05-1945

10.1385/ENDO:27:2:179

10.2174/1568026023394407

Bordt, 2001, N1E-115 mouse neuroblastoma cells express MT1 melatonin receptors and produce neurites in response to melatonin, Biochim Biophys Acta, 1499, 257, 10.1016/S0167-4889(00)00127-0

10.1146/annurev.pharmtox.39.1.53

10.1038/378783a0

10.1038/ng.277

10.1038/sj.bjp.0703130

10.1051/rnd:19990304

10.1210/en.142.10.4264

10.1210/me.13.12.2025

10.1210/jcem-64-4-865

10.1034/j.1600-079X.2000.290304.x

Cajochen, 2005, TAK-375 Takeda, Curr Opin Investig Drugs, 6, 114

Cajochen, 1997, Melatonin and S-20098 increase REM sleep and wake-up propensity without modifying NREM sleep homeostasis, Am J Physiol, 272, R1189

10.1210/en.135.1.373

10.1210/edrv-2-3-327

Cardinali, 1997, Melatonin site and mechanism of action: single or multiple?, J Pineal Res, 23, 32, 10.1111/j.1600-079X.1997.tb00332.x

10.1210/endo-91-5-1213

10.1016/S1087-0792(98)90020-X

10.1210/endo-105-2-437

10.1096/fj.02-0501fje

10.1210/jc.2004-1429

10.1046/j.1365-2826.2000.00519.x

Clemens, 1986, Development of drugs to modify the actions of melatonin, J Neural Transm Suppl, 21, 451

10.1016/S0024-3205(01)01097-9

10.1111/j.1476-5381.2009.00453.x

10.1016/S0304-3835(02)00502-5

10.1006/bbrc.1997.7482

10.1074/jbc.M002358200

10.1006/bbrc.2001.4722

Dauchy, 2003, Physiologic melatonin concentration, omega-3 fatty acids, and conjugated linoleic acid inhibit fatty acid transport in rodent hind limb skeletal muscle in vivo, Comp Med, 53, 186

10.1016/j.bioorg.2003.09.004

10.1021/jm970246n

10.1177/074873049701200603

10.1016/0163-7258(95)02020-9

10.1136/jmg.40.1.74

10.1021/jm00046a006

10.1021/jm0255872

10.2174/156802607780906799

10.1309/1T4V-CT1G-UBJP-3EHP

10.1073/pnas.91.5.1824

10.1016/S0014-2999(98)00064-8

Drazen, 2001, Melatonin enhancement of splenocyte proliferation is attenuated by luzindole, a melatonin receptor antagonist, Am J Physiol Regul Integr Comp Physiol, 280, R1476, 10.1152/ajpregu.2001.280.5.R1476

10.1159/000054684

10.1677/joe.0.1560261

10.1038/306782a0

Dubocovich, 1985, Characterization of a retinal melatonin receptor, J Pharmacol Exp Ther, 234, 395

Dubocovich, 1988, Luzindole (N-0774): a novel melatonin receptor antagonist, J Pharmacol Exp Ther, 246, 902

Dubocovich, 1988, Pharmacology and function of melatonin receptors, FASEB J, 2, 2765, 10.1096/fasebj.2.12.2842214

Dubocovich ML (1988c) Pharmacology and function of melatonin in retina, in Progress in Retinal Research ( Osborne NN Chader G eds) pp 129–151, Pergamon Press, Oxford.

10.1016/S0165-6147(00)88978-6

Dubocovich, 2006, Agomelatine targets a range of major depressive disorder symptoms, Curr Opin Investig Drugs, 7, 670

Dubocovich, 2007, Melatonin receptors: role on sleep and circadian rhythm regulation, Sleep Med, 8, 34, 10.1016/j.sleep.2007.10.007

Dubocovich ML Cardinali DP Delagrange P Krause DN Strosberg AD Sugden D Yocca FD (2000) Melatonin receptors, in The IUPHAR Compendium of Receptor Characterization and Classification, 2nd ed ( Girdlestone D ed) pp 270–277, IUPHAR Media, London.

Dubocovich ML Cardinali DP Guardiola-Lemaitre B Hagan RM Krause DN Sugden D Vanhoutte PM Yocca FD (1998a) Melatonin receptors, in The IUPHAR Compendium of Receptor Characterization and Classification pp 187–193, IUPHAR Media, London.

Dubocovich ML Delagrange P Olcese J (2009) Melatonin receptors, in IUPHAR database (IUPHAR-DB). Available at: http://www.iuphar-db.org/DATABASE/FamilyMenuForward?familyId=39 .

Dubocovich, 2005, Effect of MT1 melatonin receptor deletion on melatonin-mediated phase shift of circadian rhythms in the C57BL/6 mouse, J Pineal Res, 39, 113, 10.1111/j.1600-079X.2005.00230.x

Dubocovich ML Masana M (2003) Melatonin receptor signaling, in Encyclopedia of Hormones and Related Cell Regulators ( Henry H Norman A eds), pp 638–644, Academic Press, San Diego, CA.

Dubocovich ML Masana MI (1998) The efficacy of melatonin receptor analogues is dependent on the level of human melatonin receptor subtype expression, in Biological Clocks Mechanisms and Applications ( Touitou Y ed) pp 289–293, Elsevier Science, Amsterdam.

Dubocovich, 1999, 3H-4P-PDOT: A selective MT2 melatonin (MLT) receptor antagonist radioligand, Soc Neurosci Abstr, 25, 351

10.1007/PL00004956

10.2741/1089

10.1073/pnas.84.11.3916

Dubocovich, 1998, Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms, FASEB J, 12, 1211, 10.1096/fasebj.12.12.1211

10.1186/1471-2148-8-105

10.1016/j.tem.2007.07.001

10.1006/bbrc.1999.1308

10.1073/pnas.91.13.6133

10.1016/S0304-3940(99)00981-7

10.1139/cjpp-76-3-269

Eison, 1993, Melatonin binding sites are functionally coupled to phosphoinositide hydrolysis in Syrian hamster RPMI 1846 melanoma cells, Life Sci, 53, L393, 10.1016/0024-3205(93)90494-N

10.1081/RRS-100107144

10.1081/CBI-100107972

10.1016/j.sleep.2005.09.004

Evans, 1992, Evidence for direct vasoconstrictor activity of melatonin in “pressurized” segments of isolated caudal artery from juvenile rats, Naunyn Schmiedebergs Arch Pharmacol, 346, 362, 10.1007/BF00173553

10.1016/j.ejmech.2007.12.001

10.1021/jm980684+

10.1111/j.1600-079X.2004.00144.x

Ferguson, 2001, Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling, Pharmacol Rev, 53, 1

10.1042/BJ20042075

10.1111/j.1600-079X.2008.00565.x

10.1210/en.2004-0990

10.1021/jm020114g

10.1097/00001756-200112040-00046

10.1016/S0167-4943(96)00754-6

10.1021/jm00007a010

10.1021/jm9508189

10.1016/S0960-894X(01)80565-5

10.1016/S0960-894X(01)80566-7

10.1126/science.279.5355.1358

10.1016/0006-8993(96)00632-4

10.1038/sj.bjp.0701761

Geary, 1997, Melatonin directly constricts rat cerebral arteries through modulation of potassium channels, Am J Physiol, 273, H1530

10.1016/j.bcp.2004.01.027

10.1124/jpet.102.044990

10.1096/fj.03-1339com

10.1517/13543784.16.12.1999

10.1007/s00441-002-0576-1

Glaser, 1998, Selective MT2 melatonin receptor antagonists are inverse agonists on human mt1 melatonin receptor, FASEB J, 12, 894

10.1210/en.138.1.397

10.1093/nar/21.1.127

10.1016/0022-2836(84)90446-7

10.1016/0968-0896(96)00112-5

10.1210/en.141.3.1236

10.2174/1568026023394335

Guilleminault, 2005, P. 2.064 Efficacy of agomelatine versus venlafaxine on subjective sleep of patients with major depressive disorder, J Eur Coll Neuropsychophamacol, 15, S419, 10.1016/S0924-977X(05)80853-3

10.1016/S0165-6147(00)88985-3

Haimov, 1995, Melatonin replacement therapy of elderly insomniacs, Sleep, 18, 598, 10.1093/sleep/18.7.598

10.1385/ENDO:27:2:119

10.1210/en.132.1.285

10.1051/rnd:2005012

10.1016/0024-3205(75)90340-9

Hirata, 1974, In vitro and in vivo formation of two new metabolites of melatonin, J Biol Chem, 249, 1311, 10.1016/S0021-9258(19)42976-1

10.1016/0014-5793(92)80948-G

10.1074/jbc.R100065200

Hunt, 2001, Activation of MT(2) melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock, Am J Physiol Cell Physiol, 280, C110, 10.1152/ajpcell.2001.280.1.C110

10.1007/s12576-008-0003-9

10.1152/ajpendo.00199.2007

10.1016/0968-0896(96)00113-7

10.1021/jm000922c

10.1016/0006-8993(95)00478-9

10.1128/MCB.23.3.1054-1060.2003

10.1038/bjp.2008.184

10.1046/j.1365-2826.2003.00972.x

10.1073/pnas.0436184100

10.1016/j.mce.2007.01.015

10.1016/S0304-3835(99)00394-8

10.1097/00004850-200209000-00002

10.1111/j.1600-079X.2004.00119.x

10.1034/j.1600-079X.2000.280405.x

10.1016/0014-5793(92)80705-L

Karasek, 2002, Expression of melatonin MT(1) and MT(2) receptors, and ROR alpha(1) receptor in transplantable murine Colon 38 cancer, Neuro Endocrinol Lett, 23, 55

10.1177/0091270005283461

10.1073/pnas.85.22.8459

10.1051/rnd:19880311

10.1016/j.neuropharm.2004.09.007

10.1016/S0303-7207(02)00064-3

10.1016/0006-8993(89)90227-8

Kennaway, 1988, Structure-activity studies of melatonin analogues in prepubertal male rats, Aust J Biol Sci, 41, 393, 10.1071/BI9880393

10.1210/jc.83.3.1013

10.1152/ajpregu.00360.2001

Kennedy, 2005, Sexual function in remitted depressed patients following agomelatine and venlafaxine XR treatment, J Eur Coll Neuropsychopharmacol, 15, S440, 10.1016/S0924-977X(05)80900-9

10.1111/j.1600-079X.2004.00157.x

Klein, 1999, Serotonin N-acetyltransferase. A personal historical perspective, Adv Exp Med Biol, 460, 5, 10.1007/0-306-46814-X_2

10.1074/jbc.R600036200

10.1016/j.tips.2007.06.003

10.1111/j.1600-079X.2004.00204.x

10.1111/j.1600-079X.2007.00470.x

10.1006/bbrc.1998.9182

10.1073/pnas.93.13.6764

Kopp, 1999, The effects of melatonin on the behavioural disturbances induced by chronic mild stress in C3H/He mice, Behav Pharmacol, 10, 73, 10.1097/00008877-199902000-00007

Kräuchi, 1997, Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature, Am J Physiol, 272, R1178

Kräuchi, 2000, Functional link between distal vasodilation and sleep-onset latency?, Am J Physiol Regul Integr Comp Physiol, 278, R741, 10.1152/ajpregu.2000.278.3.R741

10.1016/0014-2999(95)00028-J

10.1016/0166-2236(90)90100-O

10.1146/annurev.pa.31.040191.003001

Krause, 1999, Melatonin and cardiovascular function, Adv Exp Med Biol, 460, 299, 10.1007/0-306-46814-X_32

10.1021/jm00012a004

10.1016/0014-5793(86)80287-3

Le Gouic, 1996, Effects of both a melatonin agonist and antagonist on seasonal changes in body mass and energy intake in the garden dormouse, Int J Obes Relat Metab Disord, 20, 661

10.1016/S0014-5793(96)01531-1

10.1016/S0968-0896(98)00147-3

Leger, 2004, Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy, Am J Med, 116, 91, 10.1016/j.amjmed.2003.07.017

Lerner, 1959, Structure of melatonin, J Am Chem Soc, 81, 6084, 10.1021/ja01531a060

10.1038/sj.emboj.7601193

10.1080/07420520500521863

10.1016/S0896-6273(00)80350-5

Lôo, 2003, [Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin-agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders.], Encephale, 29, 165

10.1097/00004850-200209000-00004

10.1016/S0014-2999(01)01369-3

10.1038/sj.bjp.0701287

10.1038/ng.288

10.1210/en.2007-1412

10.1016/S0006-2952(01)00881-4

10.1517/13543784.10.3.467

10.1177/074873049701200626

10.1016/j.febslet.2004.10.083

10.1177/074873001129002051

10.1051/rnd:19990308

Martin, 1980, Melatonin inhibition of the in vivo pituitary response to luteinizing hormone-releasing hormone in the neonatal rat, Neuroendocrinology, 31, 13, 10.1159/000123044

10.1124/jpet.302.3.1295

Masana, 2000, Circadian rhythm of mt1 melatonin receptor expression in the suprachiasmatic nucleus of the C3H/HeN mouse, J Pineal Res, 28, 185, 10.1034/j.1600-079X.2001.280309.x

10.1126/stke.2001.107.pe39

10.1016/0304-3940(88)90674-X

10.1021/jm960219h

10.1016/S0960-894X(03)00090-8

10.1016/j.bbrc.2005.05.017

10.1111/j.1600-079X.2008.00598.x

10.1111/j.1471-4159.2004.02758.x

10.1016/0169-328X(96)00017-4

10.1210/en.138.2.627

Meier, 1988, [Benzodiazepine–practice and problems of its use.], Schweizerische medizinische Wochenschrift, 118, 381

10.1007/s003359900444

10.1124/jpet.103.051797

Mills, 1992, Genetic and physical mapping on chromosome 4 narrows the localization of the gene for facioscapulohumeral muscular dystrophy (FSHD), Am J Hum Genet, 51, 432

10.1111/j.1755-5949.2008.00066.x

Miyamoto, 2004, The sleep-promoting action of ramelteon (TAK-375) in freely moving cats, Sleep, 27, 1319, 10.1093/sleep/27.7.1319

10.1016/0014-2999(95)00870-5

10.1097/YIC.0b013e3280c56b13

10.1097/01.yic.0000137184.64610.c8

10.1159/000014656

Mor, 1999, Melatonin, Curr Med Chem, 6, 501, 10.2174/0929867306666220330190146

10.1021/jm9810093

10.1016/0197-0186(94)90100-7

Morin, 1997, Melatonin high-affinity binding to alpha-1-acid glycoprotein in human serum, Pharmacology, 54, 271, 10.1159/000139495

10.1111/j.1600-079X.2007.00435.x

10.1016/S0014-2999(02)01903-9

10.1016/j.ejphar.2009.01.029

10.1111/j.1600-079X.2006.00399.x

Mulchahey, 2004, A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin, Life Sci, 75, 1843, 10.1016/j.lfs.2004.03.023

10.1007/s00125-009-1359-y

10.1016/j.lfs.2003.08.046

10.1016/0014-2999(96)00114-8

10.1210/me.15.8.1306

10.1097/00001756-199602290-00009

Nelson, 1995, Physiological roles and properties of potassium channels in arterial smooth muscle, Am J Physiol, 268, C799, 10.1152/ajpcell.1995.268.4.C799

10.1159/000071815

10.1016/S0303-7207(99)00135-5

10.1124/jpet.109.155283

Noda, 1994, The high affinity state of the beta 2-adrenergic receptor requires unique interaction between conserved and non-conserved extracellular loop cysteines, J Biol Chem, 269, 6743, 10.1016/S0021-9258(17)37438-0

10.1034/j.1600-0633.2002.290406.x

10.1038/sj.bjp.0702658

10.1074/jbc.M005141200

10.1016/S0006-2952(01)00615-3

Olcese J ed (1999) Melatonin after Four Decades: An Assessment of its Potential, Kluwer Academic/Plenum Publishers, New York.

10.1111/j.1600-079X.2009.00692.x

10.1017/S1461145707007766

10.1073/pnas.0808952105

Ozaki, 1976, Presence of melatonin in plasma and urine or pinealectomized rats, Endocrinology, 99, 641, 10.1210/endo-99-2-641

10.1111/j.1471-4159.1980.tb11272.x

Pawlikowski, 2002, Oncostatic action of melatonin: facts and question marks, Neuro Endocrinol Lett, 23, 24

10.1095/biolreprod62.4.1096

10.1034/j.1600-079X.2001.280305.x

10.1034/j.1600-079X.2002.02919.x

10.1111/j.1600-079X.2007.00426.x

10.1016/S0006-2952(99)00134-3

10.1016/0014-2999(90)90154-X

10.1016/S0166-4328(02)00235-8

Pitrosky, 1991, Effects of different doses and durations of melatonin infusions on plasma melatonin concentrations in pinealectomized Syrian hamsters: consequences at the level of sexual activity, J Pineal Res, 11, 149, 10.1111/j.1600-079X.1991.tb00471.x

10.1016/S0006-8993(02)02824-X

Popova, 1995, Melatonin receptor-mediated stimulation of phosphoinositide breakdown in chick brain slices, J Neurochem, 64, 130, 10.1046/j.1471-4159.1995.64010130.x

10.1038/ng.290

10.1016/0031-9384(68)90040-1

10.1016/0031-9384(70)90110-1

10.1016/0031-9384(70)90041-7

Quera-Salva, 2005, P. 2.102 Effect of agomelatine on the sleep EEG in patients with major depressive disorder (MMD), J Eur Coll Neuropsychopharmacol, 15, S435, 10.1016/S0924-977X(05)80891-0

Racagni, 2007, The interaction between the internal clock and antidepressant efficacy, Int Clin Psychopharmacol, 22, S9, 10.1097/01.yic.0000277957.75852.c7

10.1111/j.1600-079X.2006.00318.x

10.1016/S0304-3835(01)00873-4

10.1038/npp.2009.46

10.1177/074873049701200613

Régrigny, 1998, Melatonin improves cerebral circulation security margin in rats, Am J Physiol, 275, H139

10.1210/edrv-1-2-109

10.1210/edrv-12-2-151

Reiter, 2001, Melatonin in plants, Nutr Rev, 59, 286, 10.1111/j.1753-4887.2001.tb07018.x

10.1073/pnas.92.19.8734

10.1016/0092-8674(95)90131-0

10.1016/0896-6273(95)90090-X

10.1016/0896-6273(94)90055-8

10.1016/0165-6147(96)10005-5

10.1126/science.2845576

10.1021/jm020982d

10.1016/j.brainres.2003.12.008

10.1210/en.137.8.3469

10.1124/mol.56.5.1014

Rönnberg, 1990, Circadian and seasonal variation in human preovulatory follicular fluid melatonin concentration, J Clin Endocrinol Metab, 71, 492, 10.1210/jcem-71-2-493

10.1210/en.137.7.3033

10.1126/science.1150609

10.1210/en.142.11.4711

Ruffolo R Humphrey P Watson S Spedding M (2000) Revised NC-IUPHAR recommendations for nomenclature of receptors, in The IUPHAR Compendium of Receptor Characterization and Classification ( Ruffolo R ed) pp 7–8, IUPHAR Media, London, UK.

10.1016/j.lfs.2004.08.016

10.1677/erc.0.0100153

10.1111/j.1600-079X.2004.00169.x

10.2174/156720507779939823

10.1016/S0304-3940(01)01967-X

10.1034/j.1600-079x.2002.00841.x

10.1177/002215540205000408

Schaeffer, 1995, Melatonin and serotonin directly regulate oxytocin, insulin-like growth factor-I and progesterone secretion by cultured human granulosa cells, Adv Exp Med Biol, 395, 547

Scher, 2002, MT(1) melatonin receptor in the human retina: expression and localization, Invest Ophthalmol Vis Sci, 43, 889

10.1016/S0014-4835(03)00123-4

10.1210/jc.2002-020449

10.1159/000054670

10.1016/0888-7543(91)90361-H

10.1210/jc.2007-1128

10.1210/jc.2008-1723

10.1016/0304-3940(89)90153-5

10.1159/000014637

10.1111/j.1600-079X.1999.tb00614.x

10.1124/pr.55.2.2

10.1016/0014-2999(90)90328-4

10.1139/y03-026

10.1016/S0197-0186(99)00120-5

10.1006/geno.1995.1056

10.1124/jpet.103.049916

Song, 1997, Studies of the renal action of melatonin: evidence that the effects are mediated by 37 kDa receptors of the Mel1a subtype localized primarily to the basolateral membrane of the proximal tubule, FASEB J, 11, 93, 10.1096/fasebj.11.1.9034171

10.1021/jm960651z

10.1021/jm001125h

10.1021/jm00077a010

10.1210/me.2003-0047

10.1034/j.1600-079X.2001.300408.x

10.1007/BF01252503

Strader, 1989, Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor, J Biol Chem, 264, 13572, 10.1016/S0021-9258(18)80035-7

10.1111/j.1600-079X.2008.00593.x

10.1111/j.1600-079X.2008.00638.x

10.1677/joe.0.120R001

10.1016/0197-0186(94)90101-5

Sugden, 1995, Structural requirements at the melatonin receptor, Br J Pharmacol, 114, 618, 10.1111/j.1476-5381.1995.tb17184.x

10.1111/j.1600-0749.2004.00185.x

10.1016/S0248-4900(98)80009-9

Sugden, 1994, 2-Iodo-N-butanoyl-5-methoxytryptamine: a potent melatonin receptro agonist, Pharmacol Commun, 4, 267

10.1051/rnd:19990306

Sumaya, 2005, The antidepressant-like effect of the melatonin receptor ligand luzindole in mice during forced swimming requires expression of MT2 but not MT1 melatonin receptors, J Pineal Res, 39, 170, 10.1111/j.1600-079X.2005.00233.x

10.1126/science.3881822

10.1111/j.1600-079X.2006.00407.x

10.1007/PL00005288

10.1038/sj.bjp.0702404

10.1016/0303-7207(93)90234-B

10.1016/0024-3205(80)90450-6

10.1038/sj.bjp.0701511

10.1038/sj.bjp.0702612

10.1113/jphysiol.2003.056465

10.1210/jc.2002-021048

10.1096/fj.07-8371com

10.1016/S0006-8993(97)01446-7

10.1210/en.143.1.84

10.1002/jps.10348

10.1016/0003-2697(84)90466-4

Vanecek, 1998, Cellular mechanisms of melatonin action, Physiol Rev, 78, 687, 10.1152/physrev.1998.78.3.687

10.1210/en.130.2.701

Vanecek, 1995, Melatonin inhibition of GnRH-induced LH release from neonatal rat gonadotroph: involvement of Ca2+ not cAMP, Am J Physiol, 269, E85

10.1016/0006-8993(87)91625-8

10.1210/endo-126-3-1509

Vanhoutte, 1996, X. International Union of Pharmacology recommendations for nomenclature of new receptor subtypes, Pharmacol Rev, 48, 1

10.1111/j.1365-2125.1992.tb04039.x

10.1073/pnas.87.16.6200

Viswanathan, 1997, Melatonin receptors mediate contraction of a rat cerebral artery, Neuroreport, 8, 3847, 10.1097/00001756-199712220-00002

10.1038/nn806

10.1097/00001756-200006260-00002

10.1159/000123997

10.1210/jcem-66-3-648

10.1021/jm0005252

10.1111/j.1460-9568.2005.04408.x

10.1210/me.10.11.1478

10.1097/00001756-199612200-00022

10.1016/S0006-8993(99)01392-X

10.1016/j.brainresbull.2005.09.016

10.1210/jcem-33-1-14

10.1007/BF00692359

Witt-Enderby, 1996, Characterization and regulation of the human ML1A melatonin receptor stably expressed in Chinese hamster ovary cells, Mol Pharmacol, 50, 166

10.1002/(SICI)1097-0169(200005)46:1<28::AID-CM4>3.0.CO;2-5

10.1210/en.139.7.3064

10.1210/jc.86.10.4789

10.1016/j.neurobiolaging.2006.06.002

10.1586/14737175.6.7.957

10.1016/S1054-3589(08)61167-9

10.1002/1097-0045(200101)46:1<52::AID-PROS1008>3.0.CO;2-Z

10.1523/JNEUROSCI.0145-09.2009

10.1016/0303-7207(92)90124-O

10.1016/0014-2999(95)00684-2

10.1210/jcem-60-1-114

10.1016/S0968-0896(02)00473-X

10.1016/S0303-7207(02)00029-1

10.1016/j.brainres.2004.08.035

10.1210/en.142.9.3783

Zemlan, 2005, The efficacy and safety of the melatonin agonist beta-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial, J Clin Psychiatry, 66, 384, 10.4088/JCP.v66n0316

10.1046/j.1471-4159.1999.0722404.x